{"transactions":[{"id":804286,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":51909,"kind":"person","name":"Pagan Douglas W.","position":1,"cik":"0001628880","reported_name":"Pagan Douglas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-04-20T21:01:51.000Z","date":"2026-04-16","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest and become exercisable, if at all,  as to all of the underlying shares if (i) the average daily closing price of the Company's common stock on Nasdaq during any 30 consecutive calendar-day period during the period beginning October 16, 2026 and ending on April 16, 2030 (the \"Performance Measurement Period\"), or (ii) the stock price in a change in control transaction that occurs during the Performance Measurement Period, equals or exceeds $40 per share, in each case subject to the Reporting Person's continued service through such vesting date."}],"balance_after":100000,"derivative":{"exercise_price":16,"expiration_date":"2036-04-16","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001193125-26-164210","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1628880/000119312526164210/ownership.xml","form_type":"4"}},{"id":804285,"issuer":{"id":4435,"kind":"organization","name":"Kailera Therapeutics, Inc.","symbol":"KLRA"},"owners":[{"id":51909,"kind":"person","name":"Pagan Douglas W.","position":1,"cik":"0001628880","reported_name":"Pagan Douglas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-04-20T21:01:51.000Z","date":"2026-04-16","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options vest and become exercisable as to 25% of the underlying shares on April 16, 2027 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service through each such vesting date."}],"balance_after":100000,"derivative":{"exercise_price":16,"expiration_date":"2036-04-16","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001193125-26-164210","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1628880/000119312526164210/ownership.xml","form_type":"4"}},{"id":2456834,"issuer":{"id":131951,"kind":"organization","name":"Dicerna Pharmaceuticals Inc","symbol":"DRNA"},"owners":[{"id":51909,"kind":"person","name":"Pagan Douglas W.","position":1,"cik":"0001628880","reported_name":"Pagan Douglas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-12-29T16:21:31.000Z","date":"2021-12-28","kind":"disposition_to_issuer","acquired":false,"shares":36900,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting)."}],"balance_after":0,"derivative":{"exercise_price":24.05,"underlying":"Common Stock","underlying_shares":36900},"source":{"system":"sec-edgar","filing":"0001399529-21-000203","document":"wf-form4_164081286902607.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1399529/000139952921000203/wf-form4_164081286902607.xml","form_type":"4"}},{"id":2456833,"issuer":{"id":131951,"kind":"organization","name":"Dicerna Pharmaceuticals Inc","symbol":"DRNA"},"owners":[{"id":51909,"kind":"person","name":"Pagan Douglas W.","position":1,"cik":"0001628880","reported_name":"Pagan Douglas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-12-29T16:21:31.000Z","date":"2021-12-28","kind":"disposition_to_issuer","acquired":false,"shares":95650,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an \"Issuer Stock Option\") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting)."}],"balance_after":0,"derivative":{"exercise_price":20.79,"underlying":"Common Stock","underlying_shares":95650},"source":{"system":"sec-edgar","filing":"0001399529-21-000203","document":"wf-form4_164081286902607.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1399529/000139952921000203/wf-form4_164081286902607.xml","form_type":"4"}},{"id":2456832,"issuer":{"id":131951,"kind":"organization","name":"Dicerna Pharmaceuticals Inc","symbol":"DRNA"},"owners":[{"id":51909,"kind":"person","name":"Pagan Douglas W.","position":1,"cik":"0001628880","reported_name":"Pagan Douglas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2021-12-29T16:21:31.000Z","date":"2021-12-28","kind":"disposition_to_issuer","acquired":false,"shares":6150,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents the contingent right to receive one Share."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each Issuer RSU that was then outstanding was cancelled and converted into the right to receive a cash payment equal to (A) the Offer Price multiplied by (B) the total number of Shares subject to such Issuer RSU immediately prior to the Effective Time (without regard to vesting)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each Issuer RSU that was then outstanding was cancelled and converted into the right to receive a cash payment equal to (A) the Offer Price multiplied by (B) the total number of Shares subject to such Issuer RSU immediately prior to the Effective Time (without regard to vesting)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"At the Effective Time, each Issuer RSU that was then outstanding was cancelled and converted into the right to receive a cash payment equal to (A) the Offer Price multiplied by (B) the total number of Shares subject to such Issuer RSU immediately prior to the Effective Time (without regard to vesting)."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":6150},"source":{"system":"sec-edgar","filing":"0001399529-21-000203","document":"wf-form4_164081286902607.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1399529/000139952921000203/wf-form4_164081286902607.xml","form_type":"4"}},{"id":2456831,"issuer":{"id":131951,"kind":"organization","name":"Dicerna Pharmaceuticals Inc","symbol":"DRNA"},"owners":[{"id":51909,"kind":"person","name":"Pagan Douglas W.","position":1,"cik":"0001628880","reported_name":"Pagan Douglas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2021-12-29T16:21:31.000Z","date":"2021-12-28","kind":"disposition_to_issuer","acquired":false,"shares":20475,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents the contingent right to receive one Share."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each Issuer RSU that was then outstanding was cancelled and converted into the right to receive a cash payment equal to (A) the Offer Price multiplied by (B) the total number of Shares subject to such Issuer RSU immediately prior to the Effective Time (without regard to vesting)."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each Issuer RSU that was then outstanding was cancelled and converted into the right to receive a cash payment equal to (A) the Offer Price multiplied by (B) the total number of Shares subject to such Issuer RSU immediately prior to the Effective Time (without regard to vesting)."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"At the Effective Time, each Issuer RSU that was then outstanding was cancelled and converted into the right to receive a cash payment equal to (A) the Offer Price multiplied by (B) the total number of Shares subject to such Issuer RSU immediately prior to the Effective Time (without regard to vesting)."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":20475},"source":{"system":"sec-edgar","filing":"0001399529-21-000203","document":"wf-form4_164081286902607.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1399529/000139952921000203/wf-form4_164081286902607.xml","form_type":"4"}},{"id":2456830,"issuer":{"id":131951,"kind":"organization","name":"Dicerna Pharmaceuticals Inc","symbol":"DRNA"},"owners":[{"id":51909,"kind":"person","name":"Pagan Douglas W.","position":1,"cik":"0001628880","reported_name":"Pagan Douglas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-12-29T16:21:31.000Z","date":"2021-12-28","kind":"other","acquired":false,"shares":7775,"price":38.25,"value":297393.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of November 17, 2021, by and among the Issuer, Novo Nordisk A/S, a Danish aktieselskab (\"Novo\"), and NNUS New Research, Inc., a Delaware corporation and a wholly owned indirect subsidiary of Novo (\"Purchaser\"), to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.0001 par value per share (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of December 28, 2021 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $38.25 per Share, in cash, without interest (the \"Offer Price\") and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled."},{"field":"shares","element":"transactionShares","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of November 17, 2021, by and among the Issuer, Novo Nordisk A/S, a Danish aktieselskab (\"Novo\"), and NNUS New Research, Inc., a Delaware corporation and a wholly owned indirect subsidiary of Novo (\"Purchaser\"), to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.0001 par value per share (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of December 28, 2021 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $38.25 per Share, in cash, without interest (the \"Offer Price\") and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of November 17, 2021, by and among the Issuer, Novo Nordisk A/S, a Danish aktieselskab (\"Novo\"), and NNUS New Research, Inc., a Delaware corporation and a wholly owned indirect subsidiary of Novo (\"Purchaser\"), to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.0001 par value per share (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of December 28, 2021 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $38.25 per Share, in cash, without interest (the \"Offer Price\") and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001399529-21-000203","document":"wf-form4_164081286902607.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1399529/000139952921000203/wf-form4_164081286902607.xml","form_type":"4"}},{"id":2465428,"issuer":{"id":131951,"kind":"organization","name":"Dicerna Pharmaceuticals Inc","symbol":"DRNA"},"owners":[{"id":51909,"kind":"person","name":"Pagan Douglas W.","position":1,"cik":"0001628880","reported_name":"Pagan Douglas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2021-12-17T16:18:31.000Z","date":"2021-12-15","kind":"exercise","acquired":false,"shares":2050,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents the contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs vest over a period of four years, with 25% of the RSUs vesting on each of the first, second, third and fourth anniversaries of December 15, 2020, subject in each case to the Reporting Person's continued employment or service with the Issuer through the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The RSUs vest over a period of four years, with 25% of the RSUs vesting on each of the first, second, third and fourth anniversaries of December 15, 2020, subject in each case to the Reporting Person's continued employment or service with the Issuer through the applicable vesting date."}],"balance_after":6150,"derivative":{"underlying":"Common Stock","underlying_shares":2050},"source":{"system":"sec-edgar","filing":"0001399529-21-000178","document":"wf-form4_163977589128508.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1399529/000139952921000178/wf-form4_163977589128508.xml","form_type":"4"}},{"id":2465427,"issuer":{"id":131951,"kind":"organization","name":"Dicerna Pharmaceuticals Inc","symbol":"DRNA"},"owners":[{"id":51909,"kind":"person","name":"Pagan Douglas W.","position":1,"cik":"0001628880","reported_name":"Pagan Douglas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-12-17T16:18:31.000Z","date":"2021-12-15","kind":"tax_withholding","acquired":false,"shares":602,"price":38.05,"value":22906.1,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to cover tax withholding obligations in connection with the vesting of RSUs."}],"balance_after":7775,"source":{"system":"sec-edgar","filing":"0001399529-21-000178","document":"wf-form4_163977589128508.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1399529/000139952921000178/wf-form4_163977589128508.xml","form_type":"4"}},{"id":2465426,"issuer":{"id":131951,"kind":"organization","name":"Dicerna Pharmaceuticals Inc","symbol":"DRNA"},"owners":[{"id":51909,"kind":"person","name":"Pagan Douglas W.","position":1,"cik":"0001628880","reported_name":"Pagan Douglas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-12-17T16:18:31.000Z","date":"2021-12-15","kind":"exercise","acquired":true,"shares":2050,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents the contingent right to receive one share of the Issuer's Common Stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes shares acquired under the DRNA 2014 Employee Stock Purchase Plan in transactions that were exempt under Rule 16b-3(c)."}],"balance_after":8377,"source":{"system":"sec-edgar","filing":"0001399529-21-000178","document":"wf-form4_163977589128508.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1399529/000139952921000178/wf-form4_163977589128508.xml","form_type":"4"}},{"id":2663098,"issuer":{"id":131951,"kind":"organization","name":"Dicerna Pharmaceuticals Inc","symbol":"DRNA"},"owners":[{"id":51909,"kind":"person","name":"Pagan Douglas W.","position":1,"cik":"0001628880","reported_name":"Pagan Douglas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2021-06-17T21:37:02.000Z","date":"2021-06-15","kind":"exercise","acquired":false,"shares":6825,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents the contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Represents RSUs that vest over a period of four years, with 25% of the RSUs vesting on each of the first, second, third and fourth anniversaries of June 15, 2020, subject in each case to the Reporting Person's continued employment or service with the Issuer through the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Represents RSUs that vest over a period of four years, with 25% of the RSUs vesting on each of the first, second, third and fourth anniversaries of June 15, 2020, subject in each case to the Reporting Person's continued employment or service with the Issuer through the applicable vesting date."}],"balance_after":20475,"derivative":{"underlying":"Common Stock","underlying_shares":6825},"source":{"system":"sec-edgar","filing":"0001399529-21-000121","document":"wf-form4_162398020794290.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1399529/000139952921000121/wf-form4_162398020794290.xml","form_type":"4"}},{"id":2663097,"issuer":{"id":131951,"kind":"organization","name":"Dicerna Pharmaceuticals Inc","symbol":"DRNA"},"owners":[{"id":51909,"kind":"person","name":"Pagan Douglas W.","position":1,"cik":"0001628880","reported_name":"Pagan Douglas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-06-17T21:37:02.000Z","date":"2021-06-15","kind":"tax_withholding","acquired":false,"shares":2004,"price":35.74,"value":71622.96,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to cover tax withholding obligations in connection with the vesting of RSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes shares acquired under the DRNA 2014 Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3(c)."}],"balance_after":5760,"source":{"system":"sec-edgar","filing":"0001399529-21-000121","document":"wf-form4_162398020794290.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1399529/000139952921000121/wf-form4_162398020794290.xml","form_type":"4"}},{"id":2663096,"issuer":{"id":131951,"kind":"organization","name":"Dicerna Pharmaceuticals Inc","symbol":"DRNA"},"owners":[{"id":51909,"kind":"person","name":"Pagan Douglas W.","position":1,"cik":"0001628880","reported_name":"Pagan Douglas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-06-17T21:37:02.000Z","date":"2021-06-15","kind":"exercise","acquired":true,"shares":6825,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit (\"RSU\") represents the contingent right to receive one share of the Issuer's Common Stock."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes shares acquired under the DRNA 2014 Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3(c)."}],"balance_after":7764,"source":{"system":"sec-edgar","filing":"0001399529-21-000121","document":"wf-form4_162398020794290.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1399529/000139952921000121/wf-form4_162398020794290.xml","form_type":"4"}},{"id":2909318,"issuer":{"id":131951,"kind":"organization","name":"Dicerna Pharmaceuticals Inc","symbol":"DRNA"},"owners":[{"id":51909,"kind":"person","name":"Pagan Douglas W.","position":1,"cik":"0001628880","reported_name":"Pagan Douglas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-01-12T21:37:31.000Z","date":"2021-01-12","kind":"grant","acquired":true,"shares":36900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests in 48 substantially equal monthly installments, with the first installment vesting on the last day of January 2021, and the remaining shares vesting on the last day of each of the 47 months thereafter; subject in each case to the Reporting Person's continued employment or service with the Issuer through each applicable vesting date."}],"balance_after":36900,"derivative":{"exercise_price":24.05,"expiration_date":"2031-01-11","underlying":"Common Stock","underlying_shares":36900},"source":{"system":"sec-edgar","filing":"0001399529-21-000011","document":"wf-form4_161050543678371.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1399529/000139952921000011/wf-form4_161050543678371.xml","form_type":"4"}},{"id":2909317,"issuer":{"id":131951,"kind":"organization","name":"Dicerna Pharmaceuticals Inc","symbol":"DRNA"},"owners":[{"id":51909,"kind":"person","name":"Pagan Douglas W.","position":1,"cik":"0001628880","reported_name":"Pagan Douglas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2021-01-12T21:37:31.000Z","date":"2021-01-12","kind":"grant","acquired":true,"shares":8200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents the contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vest over a period of four years, with 25% of the RSUs vesting on each of the first, second, third and fourth anniversaries of December 15, 2020, subject in each case to the Reporting Person's continued employment or service with the Issuer through the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vest over a period of four years, with 25% of the RSUs vesting on each of the first, second, third and fourth anniversaries of December 15, 2020, subject in each case to the Reporting Person's continued employment or service with the Issuer through the applicable vesting date."}],"balance_after":8200,"derivative":{"underlying":"Common Stock","underlying_shares":8200},"source":{"system":"sec-edgar","filing":"0001399529-21-000011","document":"wf-form4_161050543678371.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1399529/000139952921000011/wf-form4_161050543678371.xml","form_type":"4"}},{"id":3126543,"issuer":{"id":131951,"kind":"organization","name":"Dicerna Pharmaceuticals Inc","symbol":"DRNA"},"owners":[{"id":51909,"kind":"person","name":"Pagan Douglas W.","position":1,"cik":"0001628880","reported_name":"Pagan Douglas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2020-06-02T20:21:53.000Z","date":"2020-06-01","kind":"grant","acquired":true,"shares":95650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options vest 25% on the first year anniversary of the vesting start date of May 26, 2020 and the remaining 75% vest in 36 substantially equal monthly installments thereafter, subject in each case to the Reporting Person's continued employment or service with the Issuer through the applicable vesting date."}],"balance_after":95650,"derivative":{"exercise_price":20.79,"expiration_date":"2030-05-31","underlying":"Common Stock","underlying_shares":95650},"source":{"system":"sec-edgar","filing":"0000899243-20-014950","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1399529/000089924320014950/doc4.xml","form_type":"4"}},{"id":3126542,"issuer":{"id":131951,"kind":"organization","name":"Dicerna Pharmaceuticals Inc","symbol":"DRNA"},"owners":[{"id":51909,"kind":"person","name":"Pagan Douglas W.","position":1,"cik":"0001628880","reported_name":"Pagan Douglas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Restricted Stock Units","published_at":"2020-06-02T20:21:53.000Z","date":"2020-06-01","kind":"grant","acquired":true,"shares":27300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents restricted stock units (\"RSUs\") that vest over a period of four years, with 25% of the RSUs vesting on each of the first, second, third and fourth anniversaries of June 15, 2020, subject in each case to the Reporting Person's continued employment or service with the Issuer through the applicable vesting date. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents restricted stock units (\"RSUs\") that vest over a period of four years, with 25% of the RSUs vesting on each of the first, second, third and fourth anniversaries of June 15, 2020, subject in each case to the Reporting Person's continued employment or service with the Issuer through the applicable vesting date. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents restricted stock units (\"RSUs\") that vest over a period of four years, with 25% of the RSUs vesting on each of the first, second, third and fourth anniversaries of June 15, 2020, subject in each case to the Reporting Person's continued employment or service with the Issuer through the applicable vesting date. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock."}],"balance_after":27300,"derivative":{"underlying":"Common Stock","underlying_shares":27300},"source":{"system":"sec-edgar","filing":"0000899243-20-014950","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1399529/000089924320014950/doc4.xml","form_type":"4"}},{"id":3323855,"issuer":{"id":8339,"kind":"organization","name":"Alaunos Therapeutics, Inc.","symbol":"TCRT"},"owners":[{"id":51909,"kind":"person","name":"Pagan Douglas W.","position":1,"cik":"0001628880","reported_name":"Pagan Douglas W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-01-03T22:11:06.000Z","date":"2019-12-31","kind":"grant","acquired":true,"shares":25281,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"100% of the shares subject to the option vest on December 31, 2020, subject to Reporting Person's continuous service with the Issuer through such date."}],"balance_after":25281,"derivative":{"exercise_price":4.72,"expiration_date":"2029-12-31","underlying":"Common Stock","underlying_shares":25281},"source":{"system":"sec-edgar","filing":"0001209191-20-001183","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1107421/000120919120001183/doc4.xml","form_type":"4"}},{"id":3323854,"issuer":{"id":8339,"kind":"organization","name":"Alaunos Therapeutics, Inc.","symbol":"TCRT"},"owners":[{"id":51909,"kind":"person","name":"Pagan Douglas W.","position":1,"cik":"0001628880","reported_name":"Pagan Douglas W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-01-03T22:11:06.000Z","date":"2019-12-31","kind":"tax_withholding","acquired":false,"shares":20054,"price":4.72,"value":94654.88,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares withheld to satisfy withholding tax obligations upon the vesting of a restricted stock grant."}],"balance_after":35943,"source":{"system":"sec-edgar","filing":"0001209191-20-001183","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1107421/000120919120001183/doc4.xml","form_type":"4"}},{"id":3323853,"issuer":{"id":8339,"kind":"organization","name":"Alaunos Therapeutics, Inc.","symbol":"TCRT"},"owners":[{"id":51909,"kind":"person","name":"Pagan Douglas W.","position":1,"cik":"0001628880","reported_name":"Pagan Douglas W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-01-03T22:11:06.000Z","date":"2019-12-31","kind":"grant","acquired":true,"shares":15890,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"15,890 shares vest on 12/31/2020."}],"balance_after":55997,"source":{"system":"sec-edgar","filing":"0001209191-20-001183","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1107421/000120919120001183/doc4.xml","form_type":"4"}},{"id":3560466,"issuer":{"id":109529,"kind":"organization","name":"Paratek Pharmaceuticals, Inc.","symbol":"PRTK"},"owners":[{"id":51909,"kind":"person","name":"Pagan Douglas W.","position":1,"cik":"0001628880","reported_name":"Pagan Douglas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-04-08T17:05:40.000Z","date":"2019-04-05","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"Represents RSUs granted to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan, pursuant to the Consulting Agreement, dated March 15, 2019, between the Issuer and the Reporting Person. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest on December 23, 2019, subject to the Reporting Person's material compliance with the Consulting Agreement and the execution of a customary release."}],"balance_after":100807,"source":{"system":"sec-edgar","filing":"0000904454-19-000351","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1178711/000090445419000351/edgar.xml","form_type":"4"}},{"id":3560465,"issuer":{"id":109529,"kind":"organization","name":"Paratek Pharmaceuticals, Inc.","symbol":"PRTK"},"owners":[{"id":51909,"kind":"person","name":"Pagan Douglas W.","position":1,"cik":"0001628880","reported_name":"Pagan Douglas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-04-08T17:05:40.000Z","date":"2019-04-05","kind":"disposition_to_issuer","acquired":false,"shares":16250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents forfeiture of PRSUs in connection with the Reporting Person's resignation as CFO of the Issuer, which were granted on February 14, 2018 and previously reporting in Table I."}],"balance_after":70807,"source":{"system":"sec-edgar","filing":"0000904454-19-000351","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178711/000090445419000351/edgar.xml","form_type":"4"}},{"id":3560464,"issuer":{"id":109529,"kind":"organization","name":"Paratek Pharmaceuticals, Inc.","symbol":"PRTK"},"owners":[{"id":51909,"kind":"person","name":"Pagan Douglas W.","position":1,"cik":"0001628880","reported_name":"Pagan Douglas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-04-08T17:05:40.000Z","date":"2019-04-05","kind":"disposition_to_issuer","acquired":false,"shares":27500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents forfeiture of performance-based RSUs (\"PRSUs\") in connection with the Reporting Person's resignation as CFO of the Issuer, which were granted on August 3, 2017 and previously reported in Table I."}],"balance_after":87057,"source":{"system":"sec-edgar","filing":"0000904454-19-000351","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178711/000090445419000351/edgar.xml","form_type":"4"}},{"id":3560463,"issuer":{"id":109529,"kind":"organization","name":"Paratek Pharmaceuticals, Inc.","symbol":"PRTK"},"owners":[{"id":51909,"kind":"person","name":"Pagan Douglas W.","position":1,"cik":"0001628880","reported_name":"Pagan Douglas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-04-08T17:05:40.000Z","date":"2019-04-05","kind":"disposition_to_issuer","acquired":false,"shares":37000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents forfeiture of RSUs in connection with the Reporting Person's resignation as CFO of the Issuer, which were granted on February 26, 2019 and previously reported in Table I."}],"balance_after":114557,"source":{"system":"sec-edgar","filing":"0000904454-19-000351","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178711/000090445419000351/edgar.xml","form_type":"4"}},{"id":3560462,"issuer":{"id":109529,"kind":"organization","name":"Paratek Pharmaceuticals, Inc.","symbol":"PRTK"},"owners":[{"id":51909,"kind":"person","name":"Pagan Douglas W.","position":1,"cik":"0001628880","reported_name":"Pagan Douglas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-04-08T17:05:40.000Z","date":"2019-04-05","kind":"disposition_to_issuer","acquired":false,"shares":19500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents forfeiture of restricted stock units (\"RSUs\") in connection with the Reporting Person's resignation as Chief Financial Officer (\"CFO\") of the Issuer, which were granted on February 14, 2018 and previously reported in Table I."}],"balance_after":151557,"source":{"system":"sec-edgar","filing":"0000904454-19-000351","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178711/000090445419000351/edgar.xml","form_type":"4"}},{"id":3626574,"issuer":{"id":109529,"kind":"organization","name":"Paratek Pharmaceuticals, Inc.","symbol":"PRTK"},"owners":[{"id":51909,"kind":"person","name":"Pagan Douglas W.","position":1,"cik":"0001628880","reported_name":"Pagan Douglas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-02-28T19:14:18.000Z","date":"2019-02-26","kind":"grant","acquired":true,"shares":37000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units granted to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest as to 1/3 of the shares subject to the restricted stock units on December 10, 2019, and on the same calendar date of each successive year thereafter until fully vested, subject to the Reporting Person's continued service with the Issuer through each vesting date."}],"balance_after":171057,"source":{"system":"sec-edgar","filing":"0000904454-19-000284","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178711/000090445419000284/edgar.xml","form_type":"4"}},{"id":3670529,"issuer":{"id":109529,"kind":"organization","name":"Paratek Pharmaceuticals, Inc.","symbol":"PRTK"},"owners":[{"id":51909,"kind":"person","name":"Pagan Douglas W.","position":1,"cik":"0001628880","reported_name":"Pagan Douglas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-02-07T16:44:28.000Z","date":"2019-02-05","kind":"sale","acquired":false,"shares":2495,"price":6.77,"value":16891.15,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Sale of shares to cover personal income tax obligations upon vesting of restricted stock unit award, pursuant to Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $6.72 to $6.85. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 2 to this Form 4."}],"balance_after":134057,"source":{"system":"sec-edgar","filing":"0000904454-19-000180","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178711/000090445419000180/edgar.xml","form_type":"4"}},{"id":3677743,"issuer":{"id":109529,"kind":"organization","name":"Paratek Pharmaceuticals, Inc.","symbol":"PRTK"},"owners":[{"id":51909,"kind":"person","name":"Pagan Douglas W.","position":1,"cik":"0001628880","reported_name":"Pagan Douglas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-02-04T16:44:11.000Z","date":"2019-02-01","kind":"grant","acquired":true,"shares":16250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents performance-based restricted stock units (\"PRSUs\") granted on February 14, 2018 to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan, which were earned on February 1, 2019.  These PRSUs will settle in shares of Common Stock on May 8, 2020, provided that the Reporting Person remains in continuous service with Paratek Pharmaceuticals, Inc. through the settlement date."}],"balance_after":136552,"source":{"system":"sec-edgar","filing":"0000904454-19-000151","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178711/000090445419000151/edgar.xml","form_type":"4"}},{"id":3714468,"issuer":{"id":8339,"kind":"organization","name":"Alaunos Therapeutics, Inc.","symbol":"TCRT"},"owners":[{"id":51909,"kind":"person","name":"Pagan Douglas W.","position":1,"cik":"0001628880","reported_name":"Pagan Douglas W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-01-03T02:17:36.000Z","date":"2018-12-31","kind":"grant","acquired":true,"shares":63350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"63,350 options vest on 12/31/2019."}],"balance_after":63350,"derivative":{"exercise_price":1.87,"expiration_date":"2028-12-31","underlying":"Common Stock","underlying_shares":63350},"source":{"system":"sec-edgar","filing":"0001209191-19-000589","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1107421/000120919119000589/doc4.xml","form_type":"4"}},{"id":3714467,"issuer":{"id":8339,"kind":"organization","name":"Alaunos Therapeutics, Inc.","symbol":"TCRT"},"owners":[{"id":51909,"kind":"person","name":"Pagan Douglas W.","position":1,"cik":"0001628880","reported_name":"Pagan Douglas W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-01-03T02:17:36.000Z","date":"2018-12-31","kind":"grant","acquired":true,"shares":40107,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"40,107 shares vest on 12/31/2019."}],"balance_after":40107,"source":{"system":"sec-edgar","filing":"0001209191-19-000589","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1107421/000120919119000589/doc4.xml","form_type":"4"}},{"id":3730870,"issuer":{"id":109529,"kind":"organization","name":"Paratek Pharmaceuticals, Inc.","symbol":"PRTK"},"owners":[{"id":51909,"kind":"person","name":"Pagan Douglas W.","position":1,"cik":"0001628880","reported_name":"Pagan Douglas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-12-14T17:42:08.000Z","date":"2018-12-12","kind":"sale","acquired":false,"shares":2918,"price":6.76,"value":19725.68,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Sale of shares to cover personal income tax obligations upon vesting of restricted stock unit award, pursuant to Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price.  The shares were sold in multiple transactions ranging from $6.55 to $7.15. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 2 to this Form 4."}],"balance_after":120302,"source":{"system":"sec-edgar","filing":"0000904454-18-000787","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178711/000090445418000787/edgar.xml","form_type":"4"}},{"id":3789989,"issuer":{"id":109529,"kind":"organization","name":"Paratek Pharmaceuticals, Inc.","symbol":"PRTK"},"owners":[{"id":51909,"kind":"person","name":"Pagan Douglas W.","position":1,"cik":"0001628880","reported_name":"Pagan Douglas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-10-16T19:58:38.000Z","date":"2018-10-15","kind":"sale","acquired":false,"shares":2784,"price":8.96,"value":24944.64,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Sale of shares to cover personal income tax obligations upon vesting of PRSUs, pursuant to Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $8.93 to $9.02. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 3 to this Form 4."}],"balance_after":123220,"source":{"system":"sec-edgar","filing":"0000904454-18-000667","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178711/000090445418000667/edgar.xml","form_type":"4"}},{"id":3789988,"issuer":{"id":109529,"kind":"organization","name":"Paratek Pharmaceuticals, Inc.","symbol":"PRTK"},"owners":[{"id":51909,"kind":"person","name":"Pagan Douglas W.","position":1,"cik":"0001628880","reported_name":"Pagan Douglas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-10-16T19:58:38.000Z","date":"2018-10-12","kind":"grant","acquired":true,"shares":6500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents performance-based restricted stock units (\"PRSUs\") granted on February 14, 2018 to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan that vested on October 12, 2018."}],"balance_after":126004,"source":{"system":"sec-edgar","filing":"0000904454-18-000667","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178711/000090445418000667/edgar.xml","form_type":"4"}},{"id":3796835,"issuer":{"id":109529,"kind":"organization","name":"Paratek Pharmaceuticals, Inc.","symbol":"PRTK"},"owners":[{"id":51909,"kind":"person","name":"Pagan Douglas W.","position":1,"cik":"0001628880","reported_name":"Pagan Douglas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-10-04T20:59:04.000Z","date":"2018-10-03","kind":"sale","acquired":false,"shares":7579,"price":9.82,"value":74425.78,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Sale of shares to cover personal income tax obligations upon vesting of PRSUs, pursuant to Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $9.75 to $9.95. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 4 to this Form 4."}],"balance_after":119504,"source":{"system":"sec-edgar","filing":"0000904454-18-000644","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178711/000090445418000644/edgar.xml","form_type":"4"}},{"id":3796834,"issuer":{"id":109529,"kind":"organization","name":"Paratek Pharmaceuticals, Inc.","symbol":"PRTK"},"owners":[{"id":51909,"kind":"person","name":"Pagan Douglas W.","position":1,"cik":"0001628880","reported_name":"Pagan Douglas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-10-04T20:59:04.000Z","date":"2018-10-02","kind":"grant","acquired":true,"shares":27500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents PRSUs granted on August 3, 2017 to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan that vested on October 2, 2018. These PRSUs will settle in shares of common stock on October 2, 2019, provided that the Reporting Person remains in continuous service with Paratek Pharmaceuticals, Inc. through the settlement date."}],"balance_after":127083,"source":{"system":"sec-edgar","filing":"0000904454-18-000644","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178711/000090445418000644/edgar.xml","form_type":"4"}},{"id":3796833,"issuer":{"id":109529,"kind":"organization","name":"Paratek Pharmaceuticals, Inc.","symbol":"PRTK"},"owners":[{"id":51909,"kind":"person","name":"Pagan Douglas W.","position":1,"cik":"0001628880","reported_name":"Pagan Douglas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-10-04T20:59:04.000Z","date":"2018-10-02","kind":"grant","acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents performance-based restricted stock units (\"PRSUs\") granted on February 2, 2017 to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan that vested on October 2, 2018."}],"balance_after":99583,"source":{"system":"sec-edgar","filing":"0000904454-18-000644","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178711/000090445418000644/edgar.xml","form_type":"4"}},{"id":3810895,"issuer":{"id":8339,"kind":"organization","name":"Alaunos Therapeutics, Inc.","symbol":"TCRT"},"owners":[{"id":51909,"kind":"person","name":"Pagan Douglas W.","position":1,"cik":"0001628880","reported_name":"Pagan Douglas W.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-09-20T20:16:15.000Z","date":"2018-09-18","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25,000 shares shall vest on each of 9/18/2019 and 9/18/2020."}],"balance_after":50000,"derivative":{"exercise_price":3,"expiration_date":"2028-09-18","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-18-051786","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1107421/000120919118051786/doc4.xml","form_type":"4"}},{"id":3966236,"issuer":{"id":109529,"kind":"organization","name":"Paratek Pharmaceuticals, Inc.","symbol":"PRTK"},"owners":[{"id":51909,"kind":"person","name":"Pagan Douglas W.","position":1,"cik":"0001628880","reported_name":"Pagan Douglas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-04-10T19:45:15.000Z","date":"2018-04-09","kind":"sale","acquired":false,"shares":5237,"price":12.7,"value":66509.9,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Sale of shares to cover personal income tax obligations upon vesting of performance-based restricted stock units, pursuant to Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $12.60 to $12.85. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 2 to this Form 4."}],"balance_after":77083,"source":{"system":"sec-edgar","filing":"0000904454-18-000289","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178711/000090445418000289/edgar.xml","form_type":"4"}},{"id":3968537,"issuer":{"id":109529,"kind":"organization","name":"Paratek Pharmaceuticals, Inc.","symbol":"PRTK"},"owners":[{"id":51909,"kind":"person","name":"Pagan Douglas W.","position":1,"cik":"0001628880","reported_name":"Pagan Douglas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-04-05T18:32:52.000Z","date":"2018-04-03","kind":"grant","acquired":true,"shares":13500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents performance-based restricted stock units granted on February 2, 2017 to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan that vested on April 3, 2018."}],"balance_after":82320,"source":{"system":"sec-edgar","filing":"0000904454-18-000273","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178711/000090445418000273/edgar.xml","form_type":"4"}},{"id":4052252,"issuer":{"id":109529,"kind":"organization","name":"Paratek Pharmaceuticals, Inc.","symbol":"PRTK"},"owners":[{"id":51909,"kind":"person","name":"Pagan Douglas W.","position":1,"cik":"0001628880","reported_name":"Pagan Douglas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-02-16T16:56:16.000Z","date":"2018-02-14","kind":"grant","acquired":true,"shares":29250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units granted to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan.  Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock.  The restricted stock units shall vest as to 1/3 of the shares subject to the restricted stock units on December 10, 2018, and on the same calendar date of each successive year thereafter until fully vested, subject to the Reporting Person's continued service with the Issuer through each vesting date."}],"balance_after":68820,"source":{"system":"sec-edgar","filing":"0000904454-18-000187","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178711/000090445418000187/edgar.xml","form_type":"4"}},{"id":4072271,"issuer":{"id":109529,"kind":"organization","name":"Paratek Pharmaceuticals, Inc.","symbol":"PRTK"},"owners":[{"id":51909,"kind":"person","name":"Pagan Douglas W.","position":1,"cik":"0001628880","reported_name":"Pagan Douglas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2018-02-07T18:11:42.000Z","date":"2018-02-05","kind":"sale","acquired":false,"shares":16291,"price":14.22,"value":231658.02,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Sale of shares to cover personal income tax obligations upon vesting of restricted stock unit award, pursuant to Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.00 to $14.43, inclusive. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":39570,"source":{"system":"sec-edgar","filing":"0000904454-18-000131","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178711/000090445418000131/edgar.xml","form_type":"4"}},{"id":4262069,"issuer":{"id":109529,"kind":"organization","name":"Paratek Pharmaceuticals, Inc.","symbol":"PRTK"},"owners":[{"id":51909,"kind":"person","name":"Pagan Douglas W.","position":1,"cik":"0001628880","reported_name":"Pagan Douglas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-07-06T16:40:34.000Z","date":"2017-07-05","kind":"sale","acquired":false,"shares":4139,"price":23.5788,"value":97592.6532,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Sale of shares to cover personal income tax obligations upon vesting of performance-based restricted stock units, pursuant to Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.45 to $23.90, inclusive. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4."}],"balance_after":55861,"source":{"system":"sec-edgar","filing":"0000904454-17-000497","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178711/000090445417000497/edgar.xml","form_type":"4"}},{"id":4262068,"issuer":{"id":109529,"kind":"organization","name":"Paratek Pharmaceuticals, Inc.","symbol":"PRTK"},"owners":[{"id":51909,"kind":"person","name":"Pagan Douglas W.","position":1,"cik":"0001628880","reported_name":"Pagan Douglas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-07-06T16:40:34.000Z","date":"2017-07-03","kind":"grant","acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents performance-based restricted stock units granted on February 2, 2017 to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan that vested on July 3, 2017."}],"balance_after":60000,"source":{"system":"sec-edgar","filing":"0000904454-17-000497","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178711/000090445417000497/edgar.xml","form_type":"4"}},{"id":4275399,"issuer":{"id":109529,"kind":"organization","name":"Paratek Pharmaceuticals, Inc.","symbol":"PRTK"},"owners":[{"id":51909,"kind":"person","name":"Pagan Douglas W.","position":1,"cik":"0001628880","reported_name":"Pagan Douglas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-06-21T16:41:36.000Z","date":"2017-06-19","kind":"sale","acquired":false,"shares":4595,"price":25,"value":114875.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan."}],"balance_after":51000,"source":{"system":"sec-edgar","filing":"0000904454-17-000450","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178711/000090445417000450/edgar.xml","form_type":"4"}},{"id":4461678,"issuer":{"id":109529,"kind":"organization","name":"Paratek Pharmaceuticals, Inc.","symbol":"PRTK"},"owners":[{"id":51909,"kind":"person","name":"Pagan Douglas W.","position":1,"cik":"0001628880","reported_name":"Pagan Douglas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-02-08T18:40:22.000Z","date":"2017-02-06","kind":"sale","acquired":false,"shares":25,"price":15.09,"value":377.25,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Sale of shares to cover personal income tax obligations upon vesting of restricted stock unit award, pursuant to Rule 10b5-1 trading plan."}],"balance_after":55595,"source":{"system":"sec-edgar","filing":"0000904454-17-000137","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1178711/000090445417000137/edgar.xml","form_type":"4"}},{"id":4461677,"issuer":{"id":109529,"kind":"organization","name":"Paratek Pharmaceuticals, Inc.","symbol":"PRTK"},"owners":[{"id":51909,"kind":"person","name":"Pagan Douglas W.","position":1,"cik":"0001628880","reported_name":"Pagan Douglas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-02-08T18:40:22.000Z","date":"2017-02-06","kind":"sale","acquired":false,"shares":1186,"price":15.05,"value":17849.3,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Sale of shares to cover personal income tax obligations upon vesting of restricted stock unit award, pursuant to Rule 10b5-1 trading plan."}],"balance_after":55620,"source":{"system":"sec-edgar","filing":"0000904454-17-000137","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1178711/000090445417000137/edgar.xml","form_type":"4"}},{"id":4461676,"issuer":{"id":109529,"kind":"organization","name":"Paratek Pharmaceuticals, Inc.","symbol":"PRTK"},"owners":[{"id":51909,"kind":"person","name":"Pagan Douglas W.","position":1,"cik":"0001628880","reported_name":"Pagan Douglas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-02-08T18:40:22.000Z","date":"2017-02-06","kind":"sale","acquired":false,"shares":17,"price":15.075,"value":256.275,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Sale of shares to cover personal income tax obligations upon vesting of restricted stock unit award, pursuant to Rule 10b5-1 trading plan."}],"balance_after":56806,"source":{"system":"sec-edgar","filing":"0000904454-17-000137","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178711/000090445417000137/edgar.xml","form_type":"4"}},{"id":4461675,"issuer":{"id":109529,"kind":"organization","name":"Paratek Pharmaceuticals, Inc.","symbol":"PRTK"},"owners":[{"id":51909,"kind":"person","name":"Pagan Douglas W.","position":1,"cik":"0001628880","reported_name":"Pagan Douglas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-02-08T18:40:22.000Z","date":"2017-02-06","kind":"sale","acquired":false,"shares":1428,"price":15.1,"value":21562.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Sale of shares to cover personal income tax obligations upon vesting of restricted stock unit award, pursuant to Rule 10b5-1 trading plan."}],"balance_after":56823,"source":{"system":"sec-edgar","filing":"0000904454-17-000137","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178711/000090445417000137/edgar.xml","form_type":"4"}},{"id":4461674,"issuer":{"id":109529,"kind":"organization","name":"Paratek Pharmaceuticals, Inc.","symbol":"PRTK"},"owners":[{"id":51909,"kind":"person","name":"Pagan Douglas W.","position":1,"cik":"0001628880","reported_name":"Pagan Douglas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-02-08T18:40:22.000Z","date":"2017-02-06","kind":"sale","acquired":false,"shares":732,"price":15.15,"value":11089.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Sale of shares to cover personal income tax obligations upon vesting of restricted stock unit award, pursuant to Rule 10b5-1 trading plan."}],"balance_after":58251,"source":{"system":"sec-edgar","filing":"0000904454-17-000137","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178711/000090445417000137/edgar.xml","form_type":"4"}},{"id":4461673,"issuer":{"id":109529,"kind":"organization","name":"Paratek Pharmaceuticals, Inc.","symbol":"PRTK"},"owners":[{"id":51909,"kind":"person","name":"Pagan Douglas W.","position":1,"cik":"0001628880","reported_name":"Pagan Douglas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-02-08T18:40:22.000Z","date":"2017-02-06","kind":"sale","acquired":false,"shares":17,"price":15.2,"value":258.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Sale of shares to cover personal income tax obligations upon vesting of restricted stock unit award, pursuant to Rule 10b5-1 trading plan."}],"balance_after":58983,"source":{"system":"sec-edgar","filing":"0000904454-17-000137","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178711/000090445417000137/edgar.xml","form_type":"4"}},{"id":4466510,"issuer":{"id":109529,"kind":"organization","name":"Paratek Pharmaceuticals, Inc.","symbol":"PRTK"},"owners":[{"id":51909,"kind":"person","name":"Pagan Douglas W.","position":1,"cik":"0001628880","reported_name":"Pagan Douglas W.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2017-02-06T19:09:19.000Z","date":"2017-02-02","kind":"grant","acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is equal to the closing sales price per share of Common Stock as reported on The Nasdaq Global Market on the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares shall vest as to 1/36 of the shares on the one-month anniversary following February 2, 2017 and on the same calendar date of each successive month thereafter until fully vested, subject to the Reporting Person's continued service to the Company at each vesting date."}],"balance_after":45000,"derivative":{"exercise_price":15.1,"expiration_date":"2027-02-01","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0000904454-17-000095","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178711/000090445417000095/edgar.xml","form_type":"4"}}]}